Biology is breaking out of the lab and clinic—and into our daily lives. Our new ability to engineer biology is transforming not just science, research, and healthcare, but how we produce our food, the materials we use, how we manufacture, and much, much more. From the latest scientific advances to the biggest trends, this show explores all the ways biology is today where the computing revolution was 50 years ago: on the precipice of revolutionizing our world in ways we are only just beginning to appreciate. Through conversations with scientists, builders, entrepreneurs, and leaders, host Olivia Webb (along with the team at Andreessen Horowitz), examines how bio is going to fundamentally transform our future.
In short, bio is eating the world.
48 Subscribers
Podcast hosts
No host has claimed this podcast yet, if you are the host you can verify ownership by claiming this podcast
© All rights reserved
Bio Eats World
Read more
48 Subscribers
Reviews
gsaustin2014
5 out of 5 stars
Great podcast covering cutting edge Bio in a clear and accessible way
Great to subscribe to - Great podcast covering cutting edge Bio in a clear and accessible way with excellent guest speakers and hosts. Easy to listen to while commuting or similar.
chris dylan emery
5 out of 5 stars
PRS Score
Absolutely fantastic breakdown of Polygenic Risk Score (PRS). Thank you!
William Y X
5 out of 5 stars
Amazing
Amazing podcast that breaks things down without sacrificing the deep dives
katiesiev
5 out of 5 stars
Perfect way to stay informed about the hottest science
I recently left biology research after nearly a decade and was looking for an easy way to keep up-to-date about new cutting-edge research. So glad I found this podcast! I love it and always learn something fascinating.
kewldown
5 out of 5 stars
So good
Great show. Great topics.
center viewpoint
5 out of 5 stars
Very intriguing topics!
The host ask interesting & thoughtful questions. The show takes scientific ideas and puts a tech spin on it that allows listeners to view science in a different way. Keep up the good work!!
Carlos!5674
5 out of 5 stars
Excellent...but s l o w d o w n
I’m hooked! Excellent, thoughtful discussion, proving once again how potential insights lie at the intersection of disciplines ripe for the picking. I’m a systems engineer in aerospace and defense so my ear may not be as tuned to the cadence and pronunciation of pharmacological or scientific names; hence, my plea. But keep it up, you are doing great. I’m a loyal but demanding listener!
Mozartoperaman
1 out of 5 stars
Spoken too fast
Couldn’t comprehend what was being said due to speed of delivery, slurring enunciation and use of medically technical words (apparently) rendering the episode impossible to follow. Slow it down and so we can evaluate and appreciate the strength of your efforts.
Mgmtech
5 out of 5 stars
Great podcast!
Fascinating and artful coverage of current events in the bio world! As a subject matter expert, I appreciate the technical details. However, the hosts manage to communicate these details in a clear and concise way without losing the bigger picture. Timely, clear, and thorough! Highly recommend!
d_h.j
5 out of 5 stars
Great podcast
I’m not a scientist or in tech, but I love hearing these super smart people talk about their work. The host and guests do a great job of communicating high level ideas in way that keeps me informed, and coming back for more.
Kelsey H-S
5 out of 5 stars
Such a delight!
This podcast discusses such timely and fascinating topics in biology, and the hosts are tremendous at their jobs! (Shout out to visible -or audible-women in STEM!) Strongly recommend a listen!
jcbw786
1 out of 5 stars
Yes, way too fast
I agree with the reviewer who said it’s just too compressed - I quit after about 5 minutes. Sounds fascinating but unlistenable.
Vanessa980
1 out of 5 stars
Way too fast
I couldnt finish the first episode because it sounded as if the interviewees voice was on fast forward.
NormanDW
5 out of 5 stars
Definitive podcast on the future of biology
Bio eats world is clearly a take on “software is eating the world” - a quote from Marc Andreessen at a16z that foretold the incredible advances enabled by software. This new “Bio eats World” podcast, enabled by a16z, is predicting similar tectonic scale breakthroughs in biology. The first episode, the biology of aging, gives remarkable arguments that indeed, aging itself may be able to be slowed. The discussion gives cogent evidence from some of the greatest biology experts. Looking forward to hearing about the next breakthroughs! I’m hooked!!!
Podcast information
- Amount of episodes
- 95
- Subscribers
- 48
- Verified
- No
- Website
- Explicit content
- No
- Episode type
- episodic
- Podcast link
- https://podvine.com/link/..
- Last upload date
- June 1, 2023
- Last fetch date
- June 3, 2023 1:56 PM
- Upload range
- WEEKLY
- Author
- Andreessen Horowitz
- Copyright
- All rights reserved
susbcribers
- Adapting Biopharma to AI with Greg MeyersToday’s episode is with Greg Meyers, EVP and Chief Digital and Technology Officer at Bristol Myers Squibb (or BMS). He is joined by a16z Bio + Health general partner Jorge Conde. Together, they talk about how AI could transform drug discovery and development at a large biopharma company—and how a company might have to adapt to harness AI; modalities they’re excited about; and Greg’s do’s and don’ts for startups looking to partner with a company like BMS.0 comments0
- Healthcare x Fintech with Julie Yoo and David HaberHealthcare payments are difficult, confusing, and opaque. But Julie and David discuss the ways that technology could change that for the better, and where they see the greatest opportunity for founders to solve big challenges. Additional reading: https://a16z.com/healthcare-meets-fintech/ https://a16z.com/2023/02/07/healthtech-x-fintechs-biggest-prize/ https://a16z.com/2022/06/01/payvidors-unbundled-opportunities-in-healthcare-fintech/0 comments0
- Bio Eats World May 18 · 34m Journal Club: Engineering Logic into CAR T Therapies with Robbie MajznerIn this episode, a16z Bio + Health investment partner Becky Pferdehirt chats with Robbie Majzner, an Assistant Professor of Pediatrics in the Division of Hematology and Oncology at Stanford, and co-founder of Link Cell Therapies. Together, they discuss Robbie's recent paper published in Nature. The paper outlines a new approach to develop logic gated intracellular network, or LINK CAR T cells, as a means to simultaneously enhance both the safety and efficacy of these novel cell therapies. Additional reading: Co-opting signalling molecules enables logic-gated control of CAR T cells, Nature0 comments0
- The Future of Cheese with Magi RichaniToday’s episode is with Magi Richani, founder and CEO of Nobell Foods. She is joined by a16z Bio + Health general partner Vijay Pande. Together, they talk about the details of engineering plants to create the future of food, why Nobell started with soybeans to produce their cheese, and her dream of finding a cheese pizza—with Nobell cheese—at any pizza shop across the country.0 comments0
- Reengineering Biotech with Vineeta AgarwalaThis is a crossover episode with The Bioverge Podcast, hosted by Neil Littman. Neil is joined by Vineeta Agarwala, general partner at a16z Bio + Health. Together, they chat about Vineeta's dual role as a clinician and investor, the adoption curve of digital therapeutics, how Vineeta thinks about platforms and a modular, engineering-driven approach to biotech, and much more.0 comments0
- Bio x American Dynamism with Katherine Boyle and David UlevitchToday’s episode is with a16z’s American Dynamism team: Katherine Boyle and David Ulevitch. Katherine is a general partner focused on national security, aerospace and defense, public safety, housing, education, and industrials. David is a general partner focused on companies promoting American dynamism, as well as enterprise and SaaS companies. They are joined by a16z Bio + Health general partner Vijay Pande, and editorial lead Olivia Webb. Together, we talk about the idea behind American Dynamism, how the American Dynamism team thinks about building within highly regulated industries, how trust is key to the procurement process, and how the team thinks about the regulation of AI.0 comments0
- Shaping Channel Partnerships with Sean DuffyToday’s episode is with Sean Duffy, cofounder and CEO of Omada Health. He is joined by a16z Bio + Health general partner Julie Yoo and investment partner Jay Rughani. Together, they talk about Sean’s three rules of partnerships, how Omada plans for large-scale implementation, and how Sean thinks about structuring the economic model of the partnership. This episode was recorded as part of our research into our forthcoming Go to Market Playbook, focused on channel partnerships. Stay tuned for that, which we’ll be releasing in the coming days at a16z.com/digital-health-builders.0 comments0
- Strategizing Channel Partnerships with Florian OttoThis week, we’re releasing two episodes about all things channel partnerships. Today’s episode is with Florian Otto, cofounder and CEO of Cedar. He is joined by a16z Bio + Health general partner Julie Yoo. In today’s episode, Florian and Julie talk about how Cedar began engaging with channel partners, what happens when things go wrong, and how the Cedar team is structured to implement and nurture these partnerships. This episode was recorded as part of our research into our forthcoming Go to Market Playbook, focused on these partnerships. Stay tuned for that, which we’ll be releasing in the coming days at a16z.com/digital-health-builders.0 comments0
- Bio Eats World Apr 13 · 45m AI and Actionable Insights for Drug Development with Daphne KollerIn this episode, Daphne Koller, founder and CEO of insitro—as well as the co-founder of Coursera, a MacArthur Award winner, and a former professor in the department of computer science at Stanford University—chats with a16z Bio + Health founding partner Vijay Pande. Together, they talk about Daphne’s career journey, how Daphne thinks about the last few decades of progress in AI, and how insitro leverages artificial intelligence and machine learning to explore biology through new models of discovery.0 comments0
- Journal Club: Remodeling oncogenic transcriptomes with Ben Cravatt and Gene YeoToday marks the reboot of our journal club series, so you can look forward to seeing these episodes as part of our regular feed. This episode is a scientific deep dive on recent research published by Ben Cravatt, Professor in the Department of Chemistry at the Scripps Research Institute and co-founder of a diverse suite of chemoproteomic companies such as Vividion and Belharra Therapeutics, and Gene Yeo, Professor of Cellular and Molecular Medicine at the University of California, San Diego and co-founder of Locana Bio, Eclipse Bio, and Trotana Therapeutics. Ben and Gene are joined by Vineeta Agarwala, general partner at a16z Bio + Health, and bio deal team member Bryan Faust. Together, they’ll discuss some unexpected mechanistic results of finding covalent binders to a class of proteins that we are just starting to understand — RNA binding proteins — and the subsequent translational implications that they described in a recent paper published by the Cravatt and Yeo labs in Nature Chemical Biology. The paper outlines a potentially new therapeutic approach that uses small molecules to fundamentally rewire transcriptional networks in cancer cells. Additional reading: Remodeling oncogenic transcriptomes by small molecules targeting NONO0 comments0
- Health System Partnerships with Tommy IbrahimIn this episode, a16z Bio + Health general partner Julie Yoo chats with Bassett Healthcare Network president and CEO Tommy Ibrahim. Together, they talk about Tommy's journey from practicing physician to health system leader, the challenges facing rural healthcare today, and how Tommy thinks about partnering and integrating with digital health entrepreneurs as a hospital executive.0 comments0
- From the Archives: The Art & Science of Biology's Future with Jennifer DoudnaIn this episode from the archives, originally published in February 2021, Jennifer Doudna, who won the 2020 Nobel Prize for the co-discovery of CRISPR-Cas9 with Emmanuelle Charpentier, chats with Vijay Pande, general partner at a16z Bio + Health. Together, they discuss the future of biology, whether discovery itself can be engineered and industrialized, and how biology can shape our future.0 comments0
- The Power of a Platform Company with Josh Mandel-BrehmIn this episode, Jorge Conde, general partner at a16z Bio + Health, talks with Josh Mandel-Brehm, founding CEO of CAMP4. Together, they talk about how CAMP4 focuses on regulatory RNA (and what that means), how Josh thinks about platform companies, and what he’s learned as the founding CEO of the company.0 comments0
- Culture and Company Building with Sam CorcosIn today's episode, Sam Corcos, CEO and cofounder of Levels Health, chats with Vijay Pande, general partner at a16z Bio + Health, about how Sam cofounded Levels, how to decide who becomes CEO if you have multiple cofounders, Levels’ approach to company culture and meetings, and how Sam thinks about the complicated world of healthcare regulations. Additional reading: Levels' public investor updates, as mentioned by Sam in the episode0 comments0
- Bio Eats World Mar 2 · 35m Payments & Payors: Fintech's Role with Kurt AdamsIn this episode, Kurt Adams, CEO of Optum Financial, chats with Daisy Wolf, investment partner for a16z Bio + Health, and Marc Andrusko, investment partner for a16z focused on fintech, about Optum Financial, how consumers might interact with fintech while seeking care or participating in healthy behaviors, and what a fintech-integrated version of the healthcare experience could look like. Additional reading from us: Payvidors, Unbundled: Opportunities in Healthcare Fintech Healthtech x Fintech’s Biggest Prize: The Financial Operating System for Healthcare0 comments0
- American Optimism with Joe LonsdaleIn this episode, Joe Lonsdale, founder and managing partner at 8VC, joins Vijay Pande, founding partner of a16z Bio + Health, and Olivia Webb, editorial lead. Together, we talk about what factors lead to innovation vs stagnation, monopoly power in healthcare, and policy ideas to incentivize change, growth, and dynamism.0 comments0
- Going to Market in Healthcare: B2C2BIn this episode, Julie Yoo, general partner, and Jay Rughani, investment partner at a16z Bio + Health, talk to Kate Ryder, founder and CEO of Maven; Amanda Rees, cofounder and CEO of Bold Health; and Bill Porter, VP and GM, International, of Butterfly Network, about their B2C2B go-to-market motion. This episode was originally recorded in late 2021, but it's still really relevant to builders, especially those exploring the B2C2B go-to-market motion. We talked about B2C2B in-depth in the second chapter of our Digital Health Builders Founder's Playbooks, also available at: https://a16z.com/digital-health-builders/ And finally, our last chapter of the Founder's Playbooks is coming soon, so hit subscribe and stay tuned!0 comments0
- Advancing the Field of ImmunotherapeuticsIn this episode, Kevin Parker, cofounder and CEO of Cartography Biosciences, joins Jorge Conde, general partner at a16z Bio + Health, and Olivia Webb, editorial lead, to discuss immuno-oncology, current challenges in drug targeting, and the mechanisms Cartography and others are using to advance the field of immunotherapeutics. This episode dives deep into the science behind immuno-oncology — but you don't necessarily have to be a scientist to follow along. You'll never look at a smoothie the same way again.0 comments0
- From Faculty to Founder: Building Startups from AcademiaIn this episode, recorded live at an a16z event, Bio + Health general partner Vineeta Agarwala moderates a panel of UCSF faculty founders, including Michelle Arkin, Jimmie Ye, and Natalia Jura (full bios below). Together, they discuss fundraising, the decision to stay in or leave academia after founding a company, and their tips for managing the IP process. You can also find a transcript of the episode—and the top 5 takeaways from this conversation—on our website, a16z.com. Michelle Arkin is a professor of pharmaceutical chemistry at UCSF, chair of the Department of Pharmaceutical Chemistry, and a co-director of the Small Molecule Discovery Center at UCSF. Professor Arkin is also a cofounder of both Elgin Therapeutics and Ambagon Therapeutics. Jimmie Ye is an associate professor of medicine at the Institute for Human Genetics at UCSF and an affiliate investigator at Gladstone Institutes. He is also the cofounder of Dropprint Genomics and Survey Genomics. Natalia Jura is a professor in the Department of Cell and Molecular Pharmacology and an investigator at the Cardiovascular Research Institute at UCSF. Professor Jura is also an associate director of the Quantitative Biosciences Institute. She is a cofounder of Rezo Therapeutics.0 comments0
- Healthspan, Lifespan, and the Biology of AgingIn this episode, Kristen Fortney, cofounder and CEO of BioAge, joins Vijay Pande, founding partner of a16z Bio + Health, and Olivia Webb, editorial lead, to discuss the biology of aging, how she started a company, and some fun things — like how long a hypothetical venture capitalist can expect to live. Additional reading: Greg Egan, whose writing inspired Kristen, has a list of his books on his website0 comments0
- Bio Eats World Jan 20 · 28m Payors and Providers Post-PandemicIn this episode, Paul Keckley, the managing editor of the Keckley Report and a health policy expert, joins Julie Yoo, general partner at a16z, and Olivia Webb, editorial lead at a16z. Together, they talk about how payors and providers are reacting to changing tailwinds, how employers are demanding more in today's market, the opportunities and challenges for startups in a consolidated industry, and what the next few years of health policy might bring. Additional reading: The Keckley Report0 comments0
- Using AI to Take Bio FartherJakob Uszkoreit and Vijay Pande discuss all things AI — from Jakob's time at Google Brain, to how humans (and computers) process language, to Inceptive’s belief in the promise of RNA, and how Jakob believes we’re entering inflection point territory. You can also find a full transcript of this episode on our website. Additional reading: Attention is All You Need A Decomposable Attention Model for Natural Language Inference0 comments0
- Expert AI as a Healthcare SuperpowerThe last few months have seen dramatic—almost magical—applications of expert generative AI released to the public. (One of those applications, incidentally, was in editing the sound mix of this episode.) But what does this mean for healthcare and bio? Vijay Pande, founding partner of a16z Bio + Health, and Marc Andreessen, cofounder of a16z, sat down for a wide-ranging discussion on AI as an additive superpower…for healthcare as well as screenplays, music, and more. You can also watch the full episode on our YouTube channel: https://www.youtube.com/@a16z.0 comments0
- Cultivated Meat: Challenges, Opportunities, FutureFrom initial inspiration in a sci-fi novel to the current state of “designing biology” in cultivated meat, SCiFi Foods cofounder and CEO Joshua March chats with Bio + Health general partner Vijay Pande and editorial lead Olivia Webb about company building, developing and iterating in biology, and what the future of cultivated meat could be.0 comments0
- AI is Here. Now What?AI is here...so why isn't it in every clinic? Eric Topol talks with a16z Bio + Health general partners Vijay Pande and Vineeta Agarwala and editorial lead Olivia Webb about what's taking so long, where AI can help patients and providers the most, what needs to happen to speed up adoption, and whether data or policy is more likely to be an obstacle. Eric has written extensively about AI in healthcare, including in his most recent book Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again. He also writes a Substack focused on Covid research, called Ground Truths, linked below. Finally, as a marker of how AI and AI adoption has (and hasn't) changed over the last few years, check out Eric's 2019 interview with Vijay on the a16z Podcast, also linked below. Ground Truths - https://erictopol.substack.com/ a16z Podcast: AI and Your Doctor, Today and Tomorrow - https://a16z.com/2019/06/13/ai-doctor-deep-medicine-topol/0 comments0
Podcast hosts
No host has claimed this podcast yet, if you are the host you can verify ownership by claiming this podcast
© All rights reserved
